Differential reliance on the polymerase among pathways may help to explain why, e.g., in urothelial tumors carrying missense mutations in ERCC2, a key component of NER, the number of SBS5 mutations increases [62], while in breast cancer cell lines lacking the TLS polymerase REV1, it decreases [59]. This evidence concerns the gene ERCC2 and breast carcinoma.